Pharmaceutical industry is an important part of our national economy. It is a combination of traditional industry and modern industry, integrating primary, secondary and tertiary industries. The pharmaceutical industry plays a very important role in safeguarding and improving people's health, improving the quality of life, family planning, disaster relief and epidemic prevention, military supplies and war preparedness, and promoting economic development and social progress. In the first half of the year, the Chinese medicine industry continued to promote variety construction, increase market development, deepen the reform of sales system, and continue to strengthen internal management. All commercial sectors have made positive progress, and the international trade sector has performed well. In the first half of the year, the company achieved an operating income of 7.244 billion yuan, an increase of 84.02% year-on-year; Operating profit was 863 million yuan, up 1 12.28% year-on-year, which was the main driving force.
At present, the concentration of pharmaceutical business in China is getting higher and higher, and the financing cost is very important. At present, the influence of the "two-vote" policy has been gradually digested, but the procurement policy with quantity has brought new challenges. The normalization of centralized procurement has a great influence on drug prices, and the scale of distribution to commercial enterprises has also been affected. Stimulated by the new epidemic, the ability of medical borrowing has improved, but the overall financial pressure is still great. Under the new situation, competition among enterprises has intensified and internal differentiation has intensified. National and regional commercial leading enterprises take over the market share of small and medium-sized enterprises by virtue of their network advantages, variety advantages and capital advantages, and constantly promote industrial concentration.
China's health expenditure has maintained an annual growth rate of more than 10%. In 20 19, the total national health expenditure was 651959 million yuan, an increase of 12.45438+0%. According to the statistics of Zhongkang Information, the medical and health market will continue to maintain steady growth in the next decade. From the perspective of supply and demand, on the one hand, with the further aggravation of population aging and the steady growth of per capita disposable income, health demand can be fully released; On the other hand, the development of medical technology, biotechnology, intelligent technology and other technologies has promoted healthy development, substantially improved the products and services on the supply side of the health industry, and met more health needs. The long-term and stable growth trend of the medical and health industry is the main tone of the industry. Based on a large amount of information and data published and provided by various related newspapers at home and abroad, Sinosteel Puhua Research Institute's Pharmaceutical Circulation Industry Report objectively analyzes and studies the market from multiple angles. On the basis of summarizing the development history of China's pharmaceutical industry, combined with various factors in the new period, the report made a careful and prudent prediction and demonstration of the development trend of the industry.